Cargando…
Review of erlotinib in the treatment of advanced non-small cell lung cancer
Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung cancer (NSCLC). Once stimulated by ligand, the downstream pathway is activated leading to cell growth, survival, and carcinoge...
Autores principales: | Ganjoo, Kristen N, Wakelee, Heather |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721286/ https://www.ncbi.nlm.nih.gov/pubmed/19707304 |
Ejemplares similares
-
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010) -
Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer
por: Wakelee, Heather, et al.
Publicado: (2018) -
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
por: Wakelee, Heather A., et al.
Publicado: (2017) -
Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
por: Li, Wei, et al.
Publicado: (2014) -
Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)